Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,564 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.
Kim BK, Bergstrom J, Loomba R, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Truong E, Yang JD, Noureddin M, Allen AM, Loomba R, Ajmera V. Kim BK, et al. Among authors: tamaki n. Hepatology. 2023 Dec 1;78(6):1858-1866. doi: 10.1097/HEP.0000000000000470. Epub 2023 May 22. Hepatology. 2023. PMID: 37203233 Clinical Trial.
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Hepatol Res. 2010 Apr;40(4):251-60. doi: 10.1111/j.1872-034X.2009.00607.x. Epub 2010 Jan 11. Hepatol Res. 2010. PMID: 20070391
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Hepatol Res. 2010 Sep;40(9):870-7. doi: 10.1111/j.1872-034X.2010.00692.x. Hepatol Res. 2010. PMID: 20887591
Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.
Itakura J, Asahina Y, Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider GJ, Izumi N. Itakura J, et al. Among authors: tamaki n. Hepatol Res. 2011 Mar;41(3):217-24. doi: 10.1111/j.1872-034X.2010.00768.x. Hepatol Res. 2011. PMID: 21338453
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N. Asahina Y, et al. Among authors: tamaki n. Hepatology. 2012 Jan;55(1):20-9. doi: 10.1002/hep.24623. Epub 2011 Nov 29. Hepatology. 2012. PMID: 21898478
Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.
Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Hosokawa T, et al. Among authors: tamaki n. World J Gastroenterol. 2013 Jan 14;19(2):249-57. doi: 10.3748/wjg.v19.i2.249. World J Gastroenterol. 2013. PMID: 23345948 Free PMC article.
1,564 results